The "malignant truth" about the recurrence of pancreatic intraductal papillary mucinous neoplasms

Archives of Surgery

Volumn 147, Issue 10, 2012, Pages 977-979

  Frampton, Adam E ^a   Pai, Madhava ^a   Krell, Jonathan ^a   Vlavianos, Panagiotis ^a   Jiao, Long R ^a   Spalding, Duncan R C ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT CHEMORADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; DISEASE FREE SURVIVAL; EARLY DIAGNOSIS; HUMAN; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; INVASIVE CARCINOMA; NOTE; OVERALL SURVIVAL; PANCREAS RESECTION; PATIENT MONITORING; PRIORITY JOURNAL; RECURRENCE RISK; SECOND LOOK SURGERY;

CARCINOMA, PANCREATIC DUCTAL; FEMALE; HUMANS; MALE; PANCREAS; PANCREATIC NEOPLASMS;

EID: 84867658985     PISSN: 00040010     EISSN: 15383644     Source Type: Journal    
DOI: 10.1001/archsurg.2012.2287     Document Type: Note

References (11)

1. Moriya T, Traverso LW. Fate of the pancreatic remnant after resection for an intraductal papillary mucinous neoplasm: a longitudinal level II cohort study. Arch Surg. 2012;147(6):528-534.
2. Traverso LW, Moriya T, Hashimoto Y. Intraductal papillary mucinous neoplasms of the pancreas: making a disposition using the natural history. Curr Gastroenterol Rep. 2012;14(2):106-111.
3. Schnelldorfer T, Sarr MG, Nagorney DM, et al. Experience with 208 resections for intraductal papillary mucinous neoplasm of the pancreas. Arch Surg. 2008;143(7):639-646. (Pubitemid 352040228)
4. Passot G, Lebeau R, Hervieu V, Ponchon T, Pilleul F, Adham M. Recurrences after surgical resection of intraductal papillary mucinous neoplasm of the pancreas: a single-center study of recurrence predictive factors. Pancreas. 2012;41(1):137-141.
5. Mino-Kenudson M, Fernández-del Castillo C, Baba Y, et al. Prognosis of invasive intraductal papillary mucinous neoplasm depends on histological and precursor epithelial subtypes. Gut. 2011;60(12):1712-1720.
6. Nakahara O, Takamori H, Iwatsuki M, et al. Carcinogenesis of intraductal papillary mucinous neoplasm of the pancreas: loss of microRNA-101 promotes overexpression of histone methyltransferase EZH2. Ann Surg Oncol. 2012;19(suppl 3):565-571. doi:10.1245/s10434-011-2068-6.
7. Matthaei H, Norris AL, Tsiatis AC, et al. Clinicopathological characteristics and molecular analyses of multifocal intraductal papillary mucinous neoplasms of the pancreas. Ann Surg. 2012;255(2):326-333.
8. Habbe N, Koorstra JB, Mendell JT, et al. MicroRNA miR-155 is a biomarker of early pancreatic neoplasia. Cancer Biol Ther. 2009;8(4):340-346.
9. Crippa S, Tamburrino D, Partelli S, et al. Total pancreatectomy: indications, different timing, and perioperative and long-term outcomes. Surgery. 2011;149(1):79-86.
10. Choi MG, Kim SW, Han SS, Jang JY, Park YH. High incidence of extrapancreatic neoplasms in patients with intraductal papillary mucinous neoplasms. Arch Surg. 2006;141(1):51-56.
11. Kawakubo K, Tada M, Isayama H, et al. Incidence of extrapancreatic malignancies in patients with intraductal papillary mucinous neoplasms of the pancreas. Gut. 2011;60(9):1249-1253.